



MANUFACTURING SUPPORT



PROCESS DEV & COMPARABILITY



ANALYTICAL DEVELOPMENT



QUANTITATIVE MODELING



QUALITY SYSTEMS



DEVICE DEVELOPMENT



REGULATORY SUPPORT



PRECLINICAL DEVELOPMENT



PROJECT & PROGRAM MGMT



MARKET RESEARCH



INTELLECTUAL PROPERTY



FINANCING & DILIGENCE

Analytical Development: Preclinical Evaluation of Candidate Potency Assay

The Ask


Potency assays should reflect efficacy-associated *in vitro* and *in vivo* activity. The client requested assistance from DHC with the design and use of preclinical studies to demonstrate biological relevance of their lead candidate *in vitro* potency assay for a clinical stage cell therapy product. This interaction demonstrates a common industry overlap between the service areas of analytical and preclinical development.

Why DHC?

- EXPAND CLIENT BANDWIDTH
- PROVIDE ADDITIONAL TECHNICAL EXPERTISE
- SOLVE EXISTING PROBLEM (REMEDiate)

DHC's Approach

- The goal of this project was to obtain proof-of-concept *in vivo* data to support the validity of the client's *in vitro* potency assay and to set assay acceptance criteria that could be used to evaluate the lot-to-lot consistency of the client's drug product.
- Dark Horse's extensive experience in preclinical modeling and *in vivo* mechanistic studies provided the necessary know-how to identify a viable strategy for establishing the physiological relevance of the client's *in vitro* potency assay.
- The first step was to evaluate existing preclinical data and identify potential strategies to demonstrate causality between the cell therapy product's activity in the candidate *in vitro* potency assay and the product's *in vivo* therapeutic activity.
- Once an optimal strategy had been selected, DHC provided the client with a detailed design of the proof-of-concept *in vivo* preclinical study, including key outcome measures and a sampling plan that would allow the program to advance beyond correlation and demonstrate a causative role of the product's hypothesized therapeutic mechanism of action.



The Impact

The outcome of this engagement was the identification of the strategy necessary to verify the physiological relevance of the lead candidate potency assay for a clinical stage cell therapy product.

Next/Concurrent Steps

- Process Development/Comparability Studies
- Preclinical Development
- Regulatory Support
- Manufacturing Support